3rd ESTRO Forum 2015 appearance of skin toxicity and in reducing the number of dermal toxicity manifestations in BCP subjected to RT. Patient satisfaction was highly positive in the majority of cases Purpose/Objective: The purpose of the current clinical trial was to evaluate efficiency of palliative external beam radiotherapy for symptomatic bone metastases from different primary tumors and to search for optimum treatment schedules. Materials and Methods: The randomized study included 427 patients treated for 616 sites of bone lesions. Breast was the primary site in 67% of cases, prostate -in 7%, lung -in 8%, renal -in 6%, other tumors, including sarcomas, melanoma, colon cancer and unknown primary site -in 12%. The most frequent treatment site was the spine -48%, followed by pelvis -34%, long bones -14% and other sites -4%. The main indication for irradiation was pain not alleviated by sistematic drug therapy (chemotherapy, target therapy, bisphosphonates).
Purpose/Objective: The assessment of response to radioembolization (RE) of liver metastases is difficult because the effect of the radiation on tumour burden is quite different from those of chemotherapeutic agents, and patients undergo this treatment after multiple systemic and regional therapies which determine dramatic changes in liver density -caused by necrosis or sclerosis.
18 F-FDG-PET/CT has been documented as a powerful tool in this respect, nonetheless there is not agreement about the optimal imaging choice (CT vs. FDG-PET/CT). We investigated the accuracy of different parameters derived from CT and 18 F-FDG PET/CT in early predicting the outcome after RE Materials and Methods: Patients with chemo-refractory liver metastases from solid tumours scheduled to receive RE underwent 18 F-FDG-PET/CT and CT scan before and 6 weeks after RE. Response to treatment was assessed in PET according to PERCIST criteria, and metabolic tumour volume (MTV), in CT according to RECIST criteria. Overall survival (OS) rates were calculated using the Kaplan Meyer method, and differences among scoring criteria were explored with the log-rank test Results: 22 patients were suitable for analysis. All patients received a single treatment of RE, with a median activity of 1.7 GBq (range 0.6-2.9) of 90 Y microspheres. Metabolic response correlated significantly with OS. For PERCIST, the median OS was 28.4 months (95 % CI, 12.4-44.4 mo) in patients with CR, 17.7 mo (5.0-30.5 mo) in patients with PR and 4.8 mo (2.9-6.8 mo) in those who had SD (see Figure 1 ). All these differences were statistically significant (p<0.05). Moreover, responders (CR+PR) had a median OS of 20.6 mo (5.7-35.5 mo) with a significant longer OS compared to those who showed SD. MTV did not produce the expected results, i.e. did not correlate with the survival. In several patients we experienced some difficulty in defining lesion margins and establishing a threshold vs the surrounding liver parenchyma. Concerning RECIST criteria, there was no straight separation between patients who responded to RE and those who did not. The median OS for patients with PR, SD and PD was 20.6 (14.5-32.8 months), 11.8 (7.9-29.6 months), and 2.7 months (0-15.5 months), respectively. Despite the median response values were separated, the statistical analysis of the survival curves did not reveal any significant difference among the four scores (CR, PR, SD, PD).
